Shares of iBio (IBIO) started to continue to fall since the company released its financial results for the second quarter of 2021 in February, why have investors lost interest in the stock? perhaps, we could find the answer in the last earnings report of the company.
On Feb 16, the company released its financial results for the fiscal quarter ended December 31, 2020. The company reported its revenues of approximately $0.7 million for this period, but the net loss attributable to its stockholders for this period was approximately $8.2 million. The company said that the total operating expenses for this period were approximately $8.3 million, and it had cash and cash equivalents of approximately $91 million as of ending December.
At this rate of cash burn, the company will run out of cash before the end of the third year. So, the company will need to do another capital raise before then, it will bring additional pressure to its stock. The company has already raised gross proceeds of $35.0 million from its shares in the last December.
Despite the company said that it is advancing its products development, including its vaccine programs. But these are unlikely to bring considerable revenues to the company in the short term, at least we haven't heard of new progress on these products in recent times. So, investors need to handle this stock with cautions.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.